small molecule

BIAXIN

CLARITHROMYCIN

Loss of exclusivity—loss of exclusivity

CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand name	BIAXIN
Active ingredient	CLARITHROMYCIN
Strength	500MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	TABLET
Route	ORAL
Modality	Small molecule
FDA approval	October 1991
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.